Fifth Third Bancorp Acquires 39,098 Shares of The Chemours Company $CC

Fifth Third Bancorp increased its holdings in The Chemours Company (NYSE:CC) by 2,624.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,588 shares of the specialty chemicals company’s stock after purchasing an additional 39,098 shares during the period. Fifth Third Bancorp’s holdings in Chemours were worth $894,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Atlas Capital Advisors Inc. bought a new stake in Chemours in the 4th quarter valued at $26,000. Aster Capital Management DIFC Ltd bought a new position in shares of Chemours during the 4th quarter valued at about $28,000. Covestor Ltd grew its position in shares of Chemours by 204.7% during the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock valued at $31,000 after purchasing an additional 1,748 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in shares of Chemours during the fourth quarter valued at about $31,000. Finally, Rothschild Investment LLC grew its position in shares of Chemours by 87.0% during the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock valued at $32,000 after purchasing an additional 1,255 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors.

Chemours Trading Up 0.2%

CC stock opened at $17.25 on Monday. The company has a market capitalization of $2.59 billion, a PE ratio of -6.53 and a beta of 1.41. The Chemours Company has a 12 month low of $10.44 and a 12 month high of $28.67. The firm’s 50-day moving average is $20.35 and its 200 day moving average is $19.92. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87.

Chemours (NYSE:CC) last announced its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.10. The company had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $0.13 EPS. On average, research analysts anticipate that The Chemours Company will post 1.18 EPS for the current year.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.0%. The ex-dividend date was Friday, May 15th. Chemours’s dividend payout ratio (DPR) is presently -13.26%.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks Research upgraded Chemours (CC) from Hold to Strong Buy, signaling stronger confidence in the company’s outlook. 3 Stocks Worth Buying After Recent Broker Ratings Upgrade
• Positive Sentiment: Analysts also raised longer-term earnings forecasts, including FY2028 EPS to $2.38 from $2.36, suggesting better profit potential over time.
• Positive Sentiment: Zacks lifted its Q4 2027 EPS estimate to $0.53 from $0.50 and increased its Q2 2028 estimate to $0.61 from $0.60, reinforcing a more constructive view on future performance.
• Neutral Sentiment: Chemours announced it will release second-quarter 2026 results after the market closes on August 4, which keeps investors focused on the upcoming earnings report. Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call
• Negative Sentiment: Zacks trimmed its Q1 2027 EPS estimate to $0.39 from $0.41 and Q3 2027 to $0.56 from $0.57, showing that not all near-term expectations are improving.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CC. Alembic Global Advisors restated an “overweight” rating and issued a $30.00 price target on shares of Chemours in a research report on Wednesday, May 13th. Morgan Stanley increased their price objective on shares of Chemours from $17.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research note on Friday, July 17th. UBS Group boosted their target price on shares of Chemours from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Mizuho decreased their target price on shares of Chemours from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.10.

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.